The conflicting roles of Axl/Mer in limiting the immune response while also promoting tumorigenesis has already been implicated as a therapeutic obstacle, and further supports the necessity for cell- or tumor-specific treatments [91]. The gene discussed is AXL; the disease is neoplasm.